EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

A patent review of peptidylarginine deiminase 4 (PAD4) inhibitors (2014–present)

Sheenagh Grace Aiken iD, Thomas Grimes iD, Shonagh Munro, Tryfon Zarganes-Tzitzikas iD, Nicholas Barrie La Thangue, Paul Edward Brennan

Expert Opinion on Therapeutic Patents · 03.06.2025 · 35 (6) · 611-621

DOI: 10.1080/13543776.2025.2484366 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Opinion on Therapeutic Patents, online erschienen am 31.03.2025. Verfasst von Sheenagh Grace Aiken und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Medicines Discovery, Nuffield Department of Medicine Research Building, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Protein-Arginine Deiminase Type 4, Enzyme Inhibitors. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Alzheimer’s Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: PAD4 mediates the post-translational modification of arginine residues into citrulline which can have profound effects on protein structure, function and interactions. Protein citrullination and neutrophil extracellular trap (NET) formation associated with increased PAD4 activity have been implicated in the development of autoimmune conditions, cardiovascular diseases, neurodegenerative disorders, and cancer. PAD4 inhibitors have been shown to suppress citrullination and NETs formation. AREAS COVERED: This review covers 10 years of industrial drug discovery campaigns reported in 28 patent applications from 10 companies. Cortellis, the World Intellectual Property Organization website, Scopus and SciFinder were used to search the patent literature using the keywords 'PAD4' and 'PAD4 inhibitor.' Most of the reported inhibitors share the same core scaffold with varied decoration of different complexity, including highly functionalized macrocycles, with some in vivo and pharmacokinetic (PK) data reported for selected examples. EXPERT OPINION: Despite PAD4's clear involvement in multiple disease pathways, its detailed mechanism remains insufficiently understood. Selective and potent compounds with improved PK properties have been provided but most research on PAD4 is still at the experimental stage or preclinical development; the most promising is JBI-1044, at the IND stage, while some companies have turned to antibodies despite considerable previous investment in small molecules.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein-Arginine Deiminase Type 4Enzyme InhibitorsHumansPatents as TopicAnimalsDrug DiscoveryDrug DevelopmentExtracellular TrapsCitrullinationProtein Processing, Post-TranslationalAutoimmune DiseasesNeoplasms

Stichwörter der Autor:innen

Autoimmunecardiovascularcitrullinationepigeneticsneutrophil extracellular trapsoncologypost-translational modificationprotein arginine deiminase

Substanzen

Protein-Arginine Deiminase Type 4Enzyme InhibitorsPADI4 protein, human

Autor:innen und Institutionen

  • Centre for Medicines Discovery, Nuffield Department of Medicine Research Building, University of Oxford, Oxford, UK.
  • Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK.
  • Alzheimer's Research UK Oxford Drug Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine Research Building, University of Oxford, Oxford, UK.
  • IngenOx, Magdalen Centre, Oxford Science Park, Oxford, UK.

ORCID-Profile: Sheenagh Grace Aiken, Thomas Grimes, Tryfon Zarganes-Tzitzikas

Förderung

  • Alzheimer’s Research UK

Zitieren

APA

Aiken, S. G., Grimes, T., Munro, S., Zarganes-Tzitzikas, T., La Thangue, N. B., & Brennan, P. E. (2025). A patent review of peptidylarginine deiminase 4 (PAD4) inhibitors (2014–present). Expert Opinion on Therapeutic Patents, 35(6), 611-621. https://doi.org/10.1080/13543776.2025.2484366

Vancouver

Aiken SG, Grimes T, Munro S, Zarganes-Tzitzikas T, La Thangue NB, Brennan PE. A patent review of peptidylarginine deiminase 4 (PAD4) inhibitors (2014–present). Expert Opinion on Therapeutic Patents. 2025;35(6):611-621. doi:10.1080/13543776.2025.2484366

BibTeX
@article{Aiken2025,
  author = {Aiken, Sheenagh Grace and Grimes, Thomas and Munro, Shonagh and Zarganes-Tzitzikas, Tryfon and La Thangue, Nicholas Barrie and Brennan, Paul Edward},
  title = {A patent review of peptidylarginine deiminase 4 (PAD4) inhibitors (2014–present)},
  journal = {Expert Opinion on Therapeutic Patents},
  year = {2025},
  volume = {35},
  number = {6},
  pages = {611--621},
  doi = {10.1080/13543776.2025.2484366}
}
Kostenlos starten →